desipramine has been researched along with Inflammation in 13 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined if intrathecal desipramine, a selective norepinephrine reuptake inhibitor, would modulate peripheral inflammation-induced hyperalgesia." | 3.70 | Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat. ( Kawamata, M; Kawamata, T; Namiki, A; Omote, K, 1999) |
| "CD-1 mice were dosed with Bacille Calmette-Guérin (BCG) and measures of body weight, locomotor activity, and immobility in the tail suspension test (TST) were made." | 1.39 | A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants. ( Clark, JA; Klee, N; Nizami, M; Platt, B; Schulenberg, J, 2013) |
| " 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain." | 1.37 | Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). ( Adedoyin, A; Bray, JA; Deecher, DC; Fensome, A; Goldberg, JA; Harrison, J; Leventhal, L; Mann, C; Mark, L; Nogle, L; O'Neill, DJ; Spangler, TB; Sullivan, NR; Terefenko, EA; Trybulski, EJ; Uveges, AJ; Vu, A; Whiteside, GT; Zhang, P, 2011) |
| "In the septic shock model, all three drugs given preventively markedly decreased circulating levels of TNF-alpha and mortality (50% mortality in fluoxetine treated group, 30% in desipramine and prednisolone treated groups versus 90% in controls)." | 1.34 | Anti-inflammatory properties of desipramine and fluoxetine. ( Bichon, F; Detoc, M; Henriquet, C; Jaffuel, D; Mathieu, M; Michel, A; Portet, K; Roumestan, C, 2007) |
| "Here we show that patients with severe sepsis exhibit an enhanced sphingolytic activity in comparison with controls [262 pmol/(mlxh) vs." | 1.33 | Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. ( Bockmeyer, CL; Brunkhorst, FM; Bunck, AC; Claus, RA; Deigner, HP; Kinscherf, R; Lösche, W, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| O'Neill, DJ | 1 |
| Adedoyin, A | 1 |
| Bray, JA | 1 |
| Deecher, DC | 1 |
| Fensome, A | 1 |
| Goldberg, JA | 1 |
| Harrison, J | 1 |
| Leventhal, L | 1 |
| Mann, C | 1 |
| Mark, L | 1 |
| Nogle, L | 1 |
| Sullivan, NR | 1 |
| Spangler, TB | 1 |
| Terefenko, EA | 1 |
| Trybulski, EJ | 1 |
| Uveges, AJ | 1 |
| Vu, A | 1 |
| Whiteside, GT | 1 |
| Zhang, P | 1 |
| Blaess, M | 1 |
| Bibak, N | 1 |
| Claus, RA | 2 |
| Kohl, M | 1 |
| Bonaterra, GA | 1 |
| Kinscherf, R | 2 |
| Laufer, S | 1 |
| Deigner, HP | 2 |
| Nozal, V | 1 |
| Martínez-González, L | 1 |
| Gomez-Almeria, M | 1 |
| Gonzalo-Consuegra, C | 1 |
| Santana, P | 1 |
| Chaikuad, A | 1 |
| Pérez-Cuevas, E | 1 |
| Knapp, S | 1 |
| Lietha, D | 1 |
| Ramírez, D | 1 |
| Petralla, S | 1 |
| Monti, B | 1 |
| Gil, C | 1 |
| Martín-Requero, A | 1 |
| Palomo, V | 1 |
| de Lago, E | 1 |
| Martinez, A | 1 |
| Nowacka-Chmielewska, MM | 1 |
| Kasprowska, D | 1 |
| Paul-Samojedny, M | 1 |
| Bielecka-Wajdman, AM | 1 |
| Barski, JJ | 1 |
| Małecki, A | 1 |
| Obuchowicz, E | 1 |
| Vircheva, S | 1 |
| Nenkova, G | 1 |
| Georgieva, A | 1 |
| Alexandrova, A | 1 |
| Tzvetanova, E | 1 |
| Mateeva, P | 1 |
| Zamfirova, R | 1 |
| Kirkova, M | 1 |
| Platt, B | 1 |
| Schulenberg, J | 1 |
| Klee, N | 1 |
| Nizami, M | 1 |
| Clark, JA | 1 |
| Deak, T | 1 |
| Bellamy, C | 1 |
| D'Agostino, LG | 1 |
| Rosanoff, M | 1 |
| McElderry, NK | 1 |
| Bordner, KA | 1 |
| Bunck, AC | 1 |
| Bockmeyer, CL | 1 |
| Brunkhorst, FM | 1 |
| Lösche, W | 1 |
| Roumestan, C | 1 |
| Michel, A | 1 |
| Bichon, F | 1 |
| Portet, K | 1 |
| Detoc, M | 1 |
| Henriquet, C | 1 |
| Jaffuel, D | 1 |
| Mathieu, M | 1 |
| Ido, Y | 1 |
| Chang, K | 1 |
| LeJeune, W | 1 |
| Tilton, RG | 1 |
| Monafo, WW | 1 |
| Williamson, JR | 1 |
| Kawamata, T | 1 |
| Omote, K | 1 |
| Kawamata, M | 1 |
| Namiki, A | 1 |
| McCleane, G | 1 |
| Westfall, DP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-11-30 | Withdrawn (stopped due to Study timeline is not feasible) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 other studies available for desipramine and Inflammation
| Article | Year |
|---|---|
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
Topics: Acute Pain; Administration, Oral; Analgesics; Animals; Benzothiazoles; Biological Availability; Cell | 2011 |
NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.
Topics: Apoptosis; Cell Line; Cells, Cultured; Ceramides; Enzyme Inhibitors; Humans; Inflammation; Lipopolys | 2018 |
TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain; Case-Control Studies; DNA-Binding Proteins; Humans; I | 2022 |
The effects of desipramine, fluoxetine, or tianeptine on changes in bulbar BDNF levels induced by chronic social instability stress and inflammation.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Desipramine; Disease Models, Anim | 2017 |
Effects of desipramine on the antioxidant status in rat tissues at carrageenan-induced paw inflammation.
Topics: Animals; Antidepressive Agents; Antioxidants; Carrageenan; Desipramine; Extremities; Inflammation; L | 2012 |
A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.
Topics: Animals; Antidepressive Agents; BCG Vaccine; Chronic Disease; Depression; Desipramine; Diazepam; Dis | 2013 |
Behavioral responses during the forced swim test are not affected by anti-inflammatory agents or acute illness induced by lipopolysaccharide.
Topics: alpha-MSH; Analysis of Variance; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic | 2005 |
Role of increased sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis.
Topics: Adult; Aged; Animals; Apoptosis; Ascorbic Acid; Blood Chemical Analysis; Ceramides; Desipramine; Dis | 2005 |
Anti-inflammatory properties of desipramine and fluoxetine.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Asthma; Cells, Cultured; Cytokines; Desipr | 2007 |
Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: implications for diabetic neuropathy.
Topics: Aldehyde Reductase; Animals; Desipramine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; En | 1997 |
Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Carrageen | 1999 |
Peripheral antinociceptive actions of desimipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat.
Topics: Analgesics, Non-Narcotic; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, | 2000 |
Antagonism by protriptyline and desipramine of the response of the vas deferens of the rat to norepinephrine, acetylcholine and potassium.
Topics: Acetylcholine; Animals; Cocaine; Desipramine; Dibenzocycloheptenes; Dose-Response Relationship, Drug | 1973 |